Forest Laboratories, Inc. (extinct)

Forest Laboratories, Inc. (extinct)

Forest Laboratories, Inc. (extinct)

Overview
Date Founded

1954

Headquarters

400 INTERPACE PARKWAY, PARSIPPANY, NJ, 07054

Type of Company

Private

Employees (Worldwide)

5,001 - 10K

Industries

Pharmaceuticals
Hospitals & Patient Services
Retail: Drug Stores
Biotechnology

Company Description

Forest has well-established franchises in multiple therapeutic areas, and we are always exploring new product opportunities that address a range of health conditions. Our principal brands include Bystolic® (nebivolol), Daliresp® (roflumilast), Lexapro® (escitalopram oxalate), Linzess™ (linaclotide), Namenda® (memantine HCl), Savella®(milnacipran HCl), Teflaro® (ceftaroline fosamil) for injection, Tudorza™ Pressair™ (aclidinium bromide inhalation powder), and Viibryd® (vilazodone HCl). Forest identifies, develops, and delivers pharmaceutical products that make a difference in people's lives. We have been extremely successful in meeting our business objectives and expanding our franchises, but we also derive satisfaction in helping to bring relief to people who are suffering. We credit our success to our innovation, integrity, and commitment to developing important products

Contact Data
Trying to get in touch with decision makers at Forest Laboratories, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Paths to Forest Laboratories, Inc.
Potential Connections via
Relationship Science
You
Forest Laboratories, Inc.
Recent Transactions
Details Hidden

Forest Laboratories, Inc. purchases Furiex Pharmaceuticals Inc.

Details Hidden

Allergan Plc purchases Forest Laboratories, Inc.

Details Hidden

Forest Laboratories, Inc. purchases Aptalis Holdings, Inc. from TPG Capital, LP, Tarrant Capital IP LLC

Transaction Advisors
Investment Advisor

Advised onAllergan Plc purchases Forest Laboratories, Inc.

Legal Advisor

Advised onAllergan Plc purchases Forest Laboratories, Inc.

Legal Advisor

Advised onForest Laboratories, Inc. purchases Furiex Pharmaceuticals Inc.

Associate

Advised onForest Laboratories, Inc. purchases Furiex Pharmaceuticals Inc.

Associate

Advised onAllergan Plc purchases Forest Laboratories, Inc.

Legal Advisor

Advised onForest Laboratories, Inc. purchases Aptalis Holdings, Inc. from TPG Capital, LP, Tarrant Capital IP LLC

Advisors & Consultants
Senior Advisor

Partner at Hildred Capital Partners LLC

Real Estate Agent

Vice Chairman at CBRE, Inc.

Legal Advisor

Founding Partner at Desmarais LLP

Key Stats and Financials As of
Market Capitalization
$25.8B
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Investments
Details Hidden

Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Details Hidden

moksha8 Pharmaceuticals, Inc. operates as a pharmaceutical company. It's products include viibryd, razapina, queopine, benexafrina, arasid, ziledon, zopina, and rispalum. The firm offers a portfolio of therapeutics for bipolar disorders and schizophrenia. The company was founded by Balkrishan Gill in 2007 and is headquartered in Berwyn, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Forest Laboratories, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Forest Laboratories, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Forest Laboratories, Inc..